Immunotherapeutic Advances for NSCLC

Immunotherapy with antibodies against PD-1 or PD-L1, either alone or in combination with chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer (NSCLC) patients without oncogenic driver alterations. These agents, namely immune checkpoint inhibitors (ICIs), have also widel...

Descripción completa

Detalles Bibliográficos
Autores principales: Massafra, Marco, Passalacqua, Maria Ilenia, Gebbia, Vittorio, Macrì, Paolo, Lazzari, Chiara, Gregorc, Vanesa, Buda, Carmelo, Altavilla, Giuseppe, Santarpia, Mariacarmela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517415/
https://www.ncbi.nlm.nih.gov/pubmed/34675481
http://dx.doi.org/10.2147/BTT.S295406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517415/
https://www.ncbi.nlm.nih.gov/pubmed/34675481
http://dx.doi.org/10.2147/BTT.S295406

Ejemplares similares